Cargando…
Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy
BACKGROUND AND AIM: The objective of this retrospective, observational, noninterventional cohort study was to investigate prognostic factors of overall survival (OS) in patients with advanced non‐small cell lung cancer (aNSCLC) and to develop a novel prognostic model. METHODS: A total of 4049 patien...
Autores principales: | Julian, Cristina, Machado, Robson J. M., Girish, Sandhya, Chanu, Pascal, Heinzmann, Dominik, Harbron, Chris, Gershon, Anda, Pfeiffer, Shannon M., Zou, Wei, Quarmby, Valerie, Zhang, Qing, Chen, Yachi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575492/ https://www.ncbi.nlm.nih.gov/pubmed/35075804 http://dx.doi.org/10.1002/cnr2.1578 |
Ejemplares similares
-
Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
por: Wang, Haowei, et al.
Publicado: (2023) -
Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
por: Malet, Julie, et al.
Publicado: (2023) -
Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019) -
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical
trials
por: Zhao, Bin, et al.
Publicado: (2020) -
Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
por: Chen, Jing, et al.
Publicado: (2021)